OBJECTIVES: New chemotherapeutic regimens (i.e. FOLFOX or FOLFIRI with molecular targeted drugs) have improved the prognosis of patients with unresectable or recurrent colorectal cancer. To estimate the prognostic impact of these chemotherapies, we examined the chronological change in survival rates of patients who underwent pulmonary metastasectomy for colorectal cancer metastasis.
INTRODUCTION
Approximately 140 000 Americans and 100 000 Japanese are diagnosed with colon or rectal cancer annually, and one third of them will die of the disease, most with metastatic tumours [1, 2] . The liver and lungs are the major organs affected by metastasis. Pulmonary resection can cure selected patients with metastatic colorectal cancer if the pulmonary metastasis can be resected; if the patient can tolerate the operation; and if the primary lesion did not show any local recurrence [3] . The postoperative prognosis of these patients depends on the biological features of the colorectal cancer, that is, the number of pulmonary metastases, the diameter of the metastatic tumour, hilar and mediastinal lymph node metastasis, tumour doubling time, disease-free interval and serum carcinoembryonic antigen (CEA) levels [4] .
On the other hand, most patients with metastatic or recurrent colorectal cancer are not eligible for surgery and undergo systemic chemotherapy. Recently, new chemotherapeutic regimens, specifically, folinic acid, 5-fluorouracil (5-FU) and oxaliplatin (FOLFOX) or folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) with bevacizumab, significantly improve the prognosis of patients with unresectable or recurrent colorectal cancer [5, 6] . We examined the impact of these regimens on the overall survival of patients who had undergone pulmonary metastasectomy for colorectal cancer metastasis. We conducted a multi-institutional study of patients who underwent metastasectomy of pulmonary metastasis over a period of about 30 years. From these retrospective data, we sought to elucidate the effect of chemotherapy on the survival of patients with pulmonary metastasis from colorectal cancer.
MATERIALS AND METHODS
We established the Metastatic Lung Tumor Study Group of Japan and collected data from patients who had undergone pulmonary metastasectomy since 1984. This multi-institutional retrospective study examined the clinicopathological data of patients with colorectal pulmonary metastasis from 26 institutions who underwent resection. This study was approved by the institutional review boards of Keio University and other institutions. We examined 1223 eligible patients who had undergone pulmonary metastasectomy with curative intent between January 1990 and March 2008. The data were previously analysed, and the results were published elsewhere [7] . The number of pulmonary metastases, maximum pulmonary tumour size, prethoracotomy serum CEA level, hilar or mediastinal lymph node involvement, completeness of pulmonary resection and history of hepatic metastasis have been analysed. We concluded that the number of tumours, the size of the tumour, the level of prethoracotomy serum CEA, lymph node involvement and completeness of resection significantly influenced the probability of postoperative survival. Adjuvant chemotherapy negatively impacted postoperative survival in that analysis. However, it was unclear whether postoperative overall survival might be changed by adjuvant therapy. We thus performed a second analysis of the data to elucidate the change in postoperative overall survival rate based on the period in which the pulmonary metastasectomy was performed.
In this study, patients were divided into three groups according to the year when the first pulmonary metastasectomy was (N = 339, Group C). The regimens of chemotherapy for colorectal cancer largely corresponded to these groups: 5-FU monotherapy was given to most of the patients in Group A, 5-FU with folinic acid was given in Group B, and FOLFOX or FOLFIRI with or without bevacizumab was mainly given to patients in Group C.
We used the Chi-square test for categorical variables and the unpaired t-test for continuous variables. The survival curves were estimated using the Kaplan-Meier method, and the differences between groups were compared using the log-rank test. Differences were considered significant when the P-value was less than 0.05. The statistical analysis was performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R 2.13.0 (R Foundation for Statistical Computing, Vienna, Austria) [8] .
RESULTS
The demographic and clinical characteristics of the patients in each group are shown in Table 1 . Resection was more frequently performed for older patients and those with a solitary pulmonary metastasis, a pulmonary metastasis with a small diameter, and an extrapulmonary metastasis, in the most recent period. Some data on postoperative chemotherapy were missing; however, a minority of patients in each group did not undergo chemotherapy after pulmonary metastasectomy. Figure 1 shows the postoperative overall survival rates of the patients after the first pulmonary metastasectomy in each group. Three-and 5-year cumulative survival rates after metastasectomy were 59 and 45% in Group A, 72and 57% in Group B and 76 and 66% in Group C, respectively. Postoperative survival significantly increased as time passed (P < 0.0001).
Postoperative chemotherapy was given to 83 patients (25%) in Group A, 89 patients (21%) in Group B and 102 patients (27%) in Group C. Three-and 5-year survival rates of patients after metastasectomy plus chemotherapy were 48 and 32% in Group A, 65 and 47% in Group B and 72 and 70% in Group C (P < 0.0001). The postoperative prognosis of patients who underwent both metastasectomy and chemotherapy in Group C was significantly better than that in the other two groups (Fig. 2) . Multivariate analysis including factors significantly affecting postoperative survival in the previous study [7] (number of tumours, maximum tumour size, CEA level, nodal involvement and completeness of resection) showed that the postoperative survival rates of patients in Group B and Group C were significantly higher than that of patients in Group A (P = 0.0038, P = 0.017, respectively). On the other hand, the postoperative overall survival rates of patients who had not undergone postoperative chemotherapy after the first pulmonary metastasectomy were not significantly different among the three groups (Fig. 3) .
Univariate analysis of our data showed that chemotherapy after pulmonary metastasectomy had a negative impact on postoperative survival (Fig. 4) . This result may be due to bias: Patients who had postoperative tumour recurrence would be more likely to receive chemotherapy. However, in a subgroup analysis of Group C, univariate analysis showed no significant difference in postoperative survival between patients who received chemotherapy and those who did not.
DISCUSSION
Pulmonary metastasis is generally a manifestation of systemic disease caused by highly advanced cancers. Certain patients with pulmonary metastasis who had undergone pulmonary resection have survived without recurrence. Patients with pulmonary metastasis from colorectal cancer can be good candidates for pulmonary metastasectomy because the lungs are thought to be the first place of spread through the bloodstream.
No randomized trials have evaluated the benefit of surgery in patients with pulmonary metastases from colorectal cancer [9] . However, multiple retrospective studies suggested that pulmonary metastasectomy had the benefit of longer survival and possibly of complete cure [10] .
Approximately 20% of patients with colorectal cancer experience distant metastases [11] . The lung is the second most frequent organ to which colorectal cancer metastasizes. Metastasectomy has been performed to cure systemic disease in the liver and lung more frequently for colorectal cancer metastases than for any other malignant neoplasm. The 5-year survival rate after pulmonary metastasectomy for colorectal cancer metastasis was reported to be 30-60% in retrospective studies [4, 10] . Postoperative prognosis depends mainly on the biological characteristics of the primary colorectal cancer. Stage of the primary tumour, liver metastasis, disease-free interval, serum CEA level, age of the patient, histological characteristics of the primary tumour, extension of lung resection, radicalness of the surgery, number of pulmonary lesions, involvement of thoracic lymph nodes, maximum tumour size, vascular invasion and some biological markers are significant prognostic factors after pulmonary metastasectomy.
In our study, the prognostic factors derived from the data analysed in this study were published previously [7] . In this study, the overall 5-year survival rate was 53.5% and the median survival time was 69.5 months. Older age, male sex, multiple metastases, larger diameter of the metastatic tumour, high CEA level, positive nodal involvement, incomplete resection and history of hepatic metastasis were poor prognostic factors as determined by univariate analysis. History of chemotherapy also had a negative impact on postoperative survival as determined by univariate analysis.
In this study, we also found that the survival rates of patients who underwent chemotherapy after pulmonary metastasectomy for colorectal cancer metastasis have increased over time. This result implies that newer chemotherapy regimens have had a positive impact on patients who had undergone pulmonary metastasectomy for colorectal cancer metastasis. We also found that the prognosis of patients who had undergone chemotherapy was poorer than those who had not undergone chemotherapy. However, this survival difference has decreased in recent years.
We have seen further advances in the treatment of metastatic colorectal cancer in the last 10 years. In the 1970s, when 5-fluorouracil was the sole effective agent, overall survival was approximately 8 months to 1 year and 5 months if the patient was not treated [12, 13] .
In the modern era, the average median survival duration has doubled, and patients often live longer than 2 years. This increase has been mainly due to the availability of new active agents, namely, irinotecan and oxaliplatin, along with the molecularly targeted drugs bevacizumab [5, 14] , cetuximab [15] and panitumumab [16] .
Accordingly, a multi-institutional study showed that overall survival of patients with metastatic colorectal cancer had increased: The median overall survival time for patients diagnosed in 1990-97 was 14.2 months, which increased to 18.0, 18.6 and 29.3 months for patients diagnosed in 1998-2000, 2001-03 and 2004-06, respectively [17] .
Several studies published a decade ago reported the influence of adjuvant chemotherapy on postoperative survival after pulmonary metastasectomy; all studies showed that chemotherapy was of no significance for long-term survival [18] [19] [20] [21] [22] , except for one study that reported marginal significance [23] . However, we found from analysis of the data that the postoperative survival rate has increased in accordance with the period when pulmonary metastasectomy was performed. The majority of the patients with pulmonary metastasectomy who underwent systemic chemotherapy eventually had systemic recurrence of colorectal cancer . Recently, neoadjuvant chemotherapy has been reported to improve the outcome of colorectal cancer patients with unresectable pulmonary metastases [17, 24] .
It is interesting that subsets of patients in our series who had not undergone chemotherapy showed no significant improvement in postoperative survival throughout the three periods. It implies that the postoperative survival of patients who underwent pulmonary metastasectomy of colorectal cancer metastasis strongly depends on chemotherapy regimens and not on the surgical procedures.
As shown in Fig. 5 , the 5-year overall survival rate of the patients with pulmonary metastasectomy of colorectal cancer metastasis and the year when the studies were published were plotted. We found a positive relationship between the 5-year survival rate and the published year. Moreover, the slope became steeper in the last 10 years (shown by a dashed line). It is interesting that the improvement of overall survival by year in patients with colorectal cancer who underwent pulmonary metastasectomy is parallel to that of patients undergoing systemic chemotherapy. Recently published phase III trials of combination regimens for patients with previously untreated metastatic colorectal cancer have demonstrated substantial improvements in overall survival, with median overall survival times ranging between 18 and 24 months with combination regimens [17] .
The limitation of this study is that it was multi-institutional and retrospective. No detailed information on the type of chemotherapy was available from the data. However, based on our data, we suggest that chemotherapy has a positive effect on survival of patients who have undergone pulmonary metastasectomy for colorectal cancer metastasis.
In conclusion, we suggest that the recent advances in chemotherapy might have contributed to improvement of postoperative overall survival of patients who had undergone pulmonary metastasectomy because of colorectal cancer. We speculate that the role of surgery in the treatment of pulmonary metastasis from colorectal cancer might change in the future. Relationship between postoperative 5-year overall survival rate of the patients who underwent pulmonary metastasectomy and published year of the article. Five-year overall survival rates of the patients with pulmonary metastasectomy for colorectal cancer metastasis and published year of the study were plotted. A positive relationship between the 5-year survival rate and the published year is shown. Moreover, the slope became steeper in the last 10 years (dashed line).
